Chronic, low-grade inflammation—coined “inflammaging”—acts as a quiet driver of systemic decline, systematically dismantling metabolic hubs like the liver as organisms grow older. In a bid to halt this deterioration, a research team out of Spain investigated a novel pharmacological intervention using a dual-drug regimen: Maraviroc, an FDA-approved CCR5 chemokine receptor antagonist typically used to treat HIV, and Rapamycin, the gold-standard mTOR inhibitor known to extend lifespan across multiple species.
To simulate severe age-related frailty and persistent inflammatory stress, the investigators utilized interleukin-10 knockout (IL-10 KO) mice. Deprived of this crucial anti-inflammatory cytokine, the animals naturally exhibit accelerated sarcopenia, muscle wasting, and profound hepatic dysfunction, serving as a highly sensitive model for therapeutic screening. The core objective was to determine whether blocking the CCR5 receptor axis, manipulating nutrient-sensing pathways, or combining both could protect liver tissue from the inflammatory cascades that characterize advanced frailty.
The transcriptomic outcomes revealed striking, widespread suppression of inflammatory and senescent signaling cascades. At the genetic level, Maraviroc, Rapamycin, and the combination treatment successfully drove down the expression of key pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), and interleukin-12 (IL-12). Furthermore, markers deeply intertwined with cellular senescence and the senescent-associated secretory phenotype (SASP)—specifically Galactosidase beta-1 (GLB-1) and the cell cycle inhibitor p21—were robustly downregulated across the treatment groups. This transcriptomic signature strongly suggests that both interventions mitigate the local cellular senescence that typically accelerates tissue degradation.
However, the proteomic reality proved far more complicated than the gene expression patterns implied. When evaluating the physical activation of these pathways via western blotting, the researchers discovered a paradoxical increase in the phosphorylated (active) forms of both mTOR and Akt within the liver tissues of treated mice. Rather than demonstrating a clean, linear shutdown of nutrient signaling, the data suggest that long-term administration triggers intricate cellular feedback loops. This study underscores the potential of repurposing chemokine blockers alongside mTOR inhibitors to arrest organ-specific aging, while flashing a warning sign about the highly unpredictable, non-linear behaviors of complex biological networks under chronic multi-drug protocols.
Actionable Insights
This study offers clear, practical takeaways for the clinical and biohacking communities focused on targeted organ preservation and mitigating inflammaging:
-
Chemokine Modulation as a Longevity Target: The CCR5/CCL5 signaling pathway represents a viable target for slowing tissue degeneration independent of or alongside traditional nutrient-sensing manipulation. Compounds that modulate this axis may help arrest chronic, low-grade inflammatory tissue decay. [Confidence: Medium]
-
Maraviroc as a Senomorphic Candidate: The capacity of Maraviroc to lower hepatic GLB-1 and p21 gene expression indicates it may function effectively as a senomorphic agent, suppressing senescent cell signaling profiles without requiring outright cellular destruction.
-
The Complexity of Drug Stacking: Simultaneously targeting distinct longevity pathways does not guarantee a simple, additive effect. Combining compounds can trigger unexpected proteomic feedback responses, such as the paradoxical elevation of phosphorylated Akt and mTOR seen here.
-
Gene vs. Protein Disconnect: Longevity protocols must not rely solely on transcriptomic markers. Suppressing a gene’s transcript level can result in a compensatory upregulation of its activated protein counterpart, requiring rigorous proteomic monitoring to confirm true systemic effects.
Source:
- Open Access Paper: Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome
- Institutions: Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, Spain; Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
- Country: Spain.
- Journal Name: PLOS ONE, Published 2024
- Impact Evaluation: The impact score of this journal is 3.7, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.